These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Treatment of Guillain-Barré syndrome by plasma exchange: proposal of a therapeutic strategy]. Raphael JC; Chevret S; Jars-Guincestre MC; Chastang C; Gajdos P Rev Neurol (Paris); 1996 May; 152(5):359-64. PubMed ID: 8881430 [TBL] [Abstract][Full Text] [Related]
23. Treatment of Guillain-Barré syndrome and CIDP. van Doorn PA J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124 [TBL] [Abstract][Full Text] [Related]
24. [Guillain-Barré syndrome: from the original description to the modern concepts]. Raphael JC; Sharshar T; Bourdain F; Léger JM Ann Med Interne (Paris); 1999 Jan; 150(1):33-41. PubMed ID: 10093660 [TBL] [Abstract][Full Text] [Related]
25. [Treatment of Guillain-Barré syndrome]. Zagar M Lijec Vjesn; 1995; 117(9-10):246-9. PubMed ID: 8643018 [TBL] [Abstract][Full Text] [Related]
26. Management of Guillain-Barré syndrome. Ferner R; Barnett M; Hughes RA Br J Hosp Med; 1987 Dec; 38(6):525-8, 530. PubMed ID: 3325121 [TBL] [Abstract][Full Text] [Related]
27. [Immunoglobulins or plasma exchange? Guillain-Barré syndrome: indications for plasma exchange and immunoglobulins]. Raphaël JC; Chevret S; Jars-Guincestre MC; Chastang C; Gajdos P Ann Med Interne (Paris); 1993; 144(8):526-31. PubMed ID: 8179242 [TBL] [Abstract][Full Text] [Related]
28. Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA Am Fam Physician; 1996 Jul; 54(1):197-200. PubMed ID: 8677835 [TBL] [Abstract][Full Text] [Related]
33. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
34. Childhood acute and chronic immune-mediated polyradiculoneuropathies. Rabie M; Nevo Y Eur J Paediatr Neurol; 2009 May; 13(3):209-18. PubMed ID: 18585069 [TBL] [Abstract][Full Text] [Related]
35. Evidence-based review of therapeutic plasma exchange in neurological disorders. Chhibber V; Weinstein R Semin Dial; 2012; 25(2):132-9. PubMed ID: 22277020 [TBL] [Abstract][Full Text] [Related]
36. [Preventive and therapeutic use of intravenous administration of immunoglobulins in intensive care patients in pediatrics]. Leititis JU Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():29-34. PubMed ID: 8499748 [TBL] [Abstract][Full Text] [Related]
37. Treatment dilemmas in Guillain-Barré syndrome. Verboon C; van Doorn PA; Jacobs BC J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):346-352. PubMed ID: 27837102 [TBL] [Abstract][Full Text] [Related]
38. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome]. Tada M; Tada M; Ishiguro H; Yagi E; Hirota K No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881 [TBL] [Abstract][Full Text] [Related]
39. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB; Phillips LH Clin Neuropharmacol; 1995 Oct; 18(5):377-90. PubMed ID: 8665552 [TBL] [Abstract][Full Text] [Related]